Novartis AG (NYSE:NVS) is one of the 11 best European stocks to invest in. On June 23, the company confirmed it had completed ...

The transaction was approved by both companies' boards and includes a significant premium over recent stock prices for ...

Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common stock, par value $0.001 ...

Basel: Novartis has announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. With the ...

Novartis has announced the expiration of its tender offer to acquire Regulus Therapeutics Inc., marking a significant step ...

Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. ("Regulus"). With the completion of the acquisition, shares of common stock ...

Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. ("Regulus").

In other recent news, Regulus Therapeutics has entered into an acquisition agreement with Novartis, with the transaction valued at approximately $1.7 billion.

Novartis today announced that its previously announced tender offer (the "Offer") by Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis ...

Novartis (LON: 0QLR) AG (SIX: NOVN) has completed its acquisition of Regulus Therapeutics Inc . (NASDAQ: RGLS), according to a press release statement filed with the Securities and Exchange Commission ...

Technological advances in the design and delivery of mRNA have catalysed the rapid development of mRNA COVID-19 vaccines by ...

Regulus Therapeutics Inc has a consensus price target of $7.71 based on the ratings of 7 analysts. The high is $11 issued by Canaccord Genuity on April 30, 2025.The low is $3 issued by Wells Fargo ...